Physician profile
David Brodner
NPI 1144284902
$209,170.33
in general payments reported to CMS, 2019-2025
22 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $22K · 2021: $54K · 2022: $36K · 2023: $422 · 2024: $553 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250 · Travel and Lodging: $600 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.19 |
| Travel and Lodging | $599.82 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $193,122.01 | 2019-2025 | Scopis Ent, Xpress Loprofile, Clarifix Cryotherapy Device |
| Nestle Healthcare Nutrition INC. | $9,250.00 | 2021-2022 | |
| Aerin Medical INC. | $2,606.31 | 2020-2025 | |
| Optinose US, INC. | $902.53 | 2019-2025 | |
| Medical Device Business Services, INC. | $781.23 | 2019 | |
| Acclarent, INC | $607.80 | 2019-2020 | |
| Gyrus Acmi, INC. | $525.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $386.39 | 2020-2025 | Xywav |
| Medtronic, INC. | $205.01 | 2024-2025 | Propel |
| Medtronic USA, INC. | $169.11 | 2019 | |
| Glaxosmithkline, LLC. | $115.53 | 2022-2025 | Nucala |
| Lilly USA, LLC | $105.59 | 2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $78.46 | 2022-2024 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $54.41 | 2025 | Lumryz |
| Fisher & Paykel Healthcare INC | $53.52 | 2023 | Fisher & Paykel Healthcare |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $49.74 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Resmed Corp | $45.28 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $36.93 | 2024 | Dupixent |
| Inspire Medical Systems, INC. | $23.30 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $18.58 | 2023 | |
| Smith+Nephew, INC. | $17.79 | 2024 | |
| Shire North American Group INC | $15.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brodner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.